COMMUNIQUÉS West-GlobeNewswire

Little Leaves Behavioral Services Expands in Maryland and Virginia

11/03/2025 - 13:51

Four new ABA therapy centers will open this summer to meet growing need for high-quality, early intervention resources for young children with autism SILVER SPRING, Md., March 11, 2025 (GLOBE NEWSWIRE) -- Little Leaves [...]

AIM ImmunoTech Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

11/03/2025 - 13:45

On-demand video webcast now available Includes latest updates on pancreatic cancer and bird flu clinical trials OCALA, Fla., March 11, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “ [...]

GRI Bio Regains Compliance with Nasdaq’s Minimum Bid Price Rule

11/03/2025 - 13:35

LA JOLLA, CA, March 11, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the [...]

Coeptis Therapeutics Secures Worldwide Development and Commercialization Rights to Next-Generation GEAR™ Cell Therapy Platform Strengthening its High-Impact Precision Immuno-Oncology Pipeline

11/03/2025 - 13:34

• COEP forms GEAR Therapeutics, as a majority-owned subsidiary, to advance GEAR-modified natural killer (NK) cells into first-in-human studies for broad range of cancers and other therapeutic modalities. WEXFORD, Pa., [...]

Kaerus Bioscience Successfully Completes Phase 1 Trial and Demonstrates Proof of Mechanism with its Novel BK Channel Modulator KER-0193 being developed for Fragile X Syndrome

11/03/2025 - 13:33

LONDON, March 11, 2025 (GLOBE NEWSWIRE) -- Kaerus Bioscience ( www.kaerusbio.com ), a clinical-stage biopharmaceutical company created by Medicxi for the development of therapeutics for rare genetic syndromes of [...]

Druid City Vital Care Recognized at Vital Care Infusion Services Annual Conference

10/03/2025 - 22:50

TUSCALOOSA, Ala., March 10, 2025 (GLOBE NEWSWIRE) -- Druid City Vital Care (“Druid City”) was recently recognized at the Vital Care Infusion Services annual conference in Orlando, FL. Three locations -- Tuscaloosa, AL, [...]

LifeMD Reports Fourth Quarter 2024 Results

10/03/2025 - 22:30

Consolidated revenues increased 43% year-over-year to $64.3 million with telehealth revenue up 60% Adjusted EBITDA increased 78% to $9.0 million Telehealth adjusted EBITDA increased 396% to $5.9 million Full-year cash [...]

Royalty Financing with HCRx: GENFIT Announces Approval of the Amendment of the Terms and Conditions of its 2025 OCEANEs

10/03/2025 - 22:10

All resolutions approved by bondholders Closing of Royalty Financing and receipt of first €130 million instalment expected shortly Upon closing of the Royalty Financing, GENFIT will implement the Repurchase of the 2025 [...]

Royalty Financing avec HCRx : GENFIT annonce l’approbation de la modification des modalités de ses OCEANEs 2025

10/03/2025 - 22:10

Approbation de toutes les résolutions par les porteurs d’OCEANEs 2025 Closing du Royalty Financing et réception de la première tranche de 130 millions d’euros attendus prochainement À la suite du closing du Royalty [...]

Nyxoah to Release Fourth Quarter and Financial Year 2024 Financial Results on March 13, 2025

10/03/2025 - 22:05

Nyxoah to Release Fourth Quarter and Financial Year 2024 Financial Results on March 13, 2025 Mont-Saint-Guibert, Belgium – Monday, March 10, 2025, 10:05pm CET / 5:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“ [...]

Nyxoah Publiera ses Résultats Financiers du Quatrième Trimestre et de l’Exercice 2024 le 13 Mars 2025

10/03/2025 - 22:05

Nyxoah Publiera ses Résultats Financiers du Quatrième Trimestre et de l’Exercice 2024 le 13 Mars 2025 Mont-Saint-Guibert, Belgique – 10 mars 2025, 22h05 CET / 17h05 ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (« [...]

Viemed Healthcare Announces Record 2024 Financial Results

10/03/2025 - 22:00

LAFAYETTE, La., March 10, 2025 (GLOBE NEWSWIRE) -- Viemed Healthcare, Inc. (the “Company” or “Viemed”) (NASDAQ:VMD), a national leader in respiratory care and technology-enabled home medical equipment services, [...]

Crinetics Pharmaceuticals Announces March 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

10/03/2025 - 21:36

SAN DIEGO, March 10, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on March 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock [...]

Coherus BioSciences Reports Fourth Quarter, Full Year 2024 Financial Results and Provides Business Update

10/03/2025 - 21:12

– Annual net revenue increased 4% to $267.0 million in 2024, despite significant divestitures – – UDENYCA ® net revenue increased 62% year-over-year – – LOQTORZI ® net revenue increased 29% quarter-over-quarter – – [...]

OnKure Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

10/03/2025 - 21:05

— PIKture-01 trial update including additional PK data, mature single agent and initial combination data expected in the second half of 2025; reported encouraging preliminary data in December 2024 — Expansion of PI3K a [...]

The Ensign Group to Present at the 35th Annual Oppenheimer Healthcare MedTech & Services Conference on March 18, 2025

10/03/2025 - 21:05

SAN JUAN CAPISTRANO, Calif., March 10, 2025 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign™ group of companies, which invest in and provide skilled nursing and senior living [...]

CervoMed Announces Positive Results from the Extension Phase of its Phase 2b Clinical Study of Neflamapimod in Patients with Dementia with Lewy Bodies

10/03/2025 - 21:05

A new batch of neflamapimod capsules led to increased plasma drug concentrations and demonstrated improvement (p<0.001 vs. old capsules; p=0.003 vs. placebo) on the primary outcome measure, change from baseline in [...]

Tenaya Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

10/03/2025 - 21:05

Dosing Initiated in Cohort 2 of the MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 for Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy MyPEAK-1 Cohort 1 Data Accepted for Late-Breaker Presentation at the [...]

Mineralys Therapeutics Announces Proposed Public Offering of Common Stock

10/03/2025 - 21:01

RADNOR, Pa., March 10, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD [...]